Contents. Part 1. Peritoneal Carcinomatosis: Basic Concepts
|
|
- Sheryl Lee
- 5 years ago
- Views:
Transcription
1 Contents Part 1. Peritoneal Carcinomatosis: Basic Concepts 1. Structure and Function of Mesothelial Cells... 1 Introduction... 1 Structure of Mesothelial Cells... 1 Mesothelial Cell Functions... 3 Slippery Protective Layer... 3 Inflammation and Immune Response... 4 Tissue Repair... 6 Fibrin Regulation... 6 Role of Mesothelial Cells in Tumour Dissemination... 7 Cell Adhesion... 7 Cell Invasion Tumour Growth Summary and Conclusions References Molecular Biology of Peritoneal Carcinomatosis Introduction Peritoneal Tumour Dissemination Mesothelial Adhesion Mesothelial Invasion Stromal Invasion and Proliferation Tumour-Peritoneal Angiogenesis Summary References Role of Adhesion Molecules in Locoregional Cancer Spread The Micro-ecosystem of Peritoneal Carcinomatosis Homotypic Cell-Cell Adhesion by the Cadherins Heterotypic Cell-Cell and Cell-Matrix Adhesion by the Integrins Other Adhesion Compounds relevant for Peritoneal Carcinomatosis CD44 and Hyaluronate Sialyl Lewis and E-selectin CA 125 and Mesothelin L1 and Neuropilin Other Adhesion Molecules in the Peritoneum Conclusion and Future Perspectives Acknowledgements References... 45
2 X Contents 4. Surgical Trauma, Minimal Residual Disease and Locoregional Cancer Recurrence Introduction Minimal Residual Disease following Surgery Tumour Associated Factors Surgery Related Factors Tumour Seeding during Laparoscopy Postoperative Factors The Link between Residual Tumour Growth and Surgery The importance of Inflammation Surgery and Tumour Dormancy Prevention and Treatment of Residual Tumour Growth Prevention of Surgical Trauma Nonspecific Intraperitoneal Therapy Intraperitoneal Chemotherapy Inhibition of the Angiogenic Switch and Reversal of Tumour Dormancy.. 59 Inhibition of the Inflammatory Response Inhibition of Adhesion of Free Intraperitoneal Cancer Cells Summary and Conclusion References Pseudomyxoma Peritonei Syndrome: Classification of Appendiceal Mucinous Tumours Introduction Mucocele Mucosal Hyperplasia and Hyperplastic Polyp Serrated Adenoma (Mixed Hyperplastic-Adenomatous Polyp) Mucinous Adenoma (Mucinous Cystadenoma) Mucinous Neoplasm of Uncertain Malignant Potential (M-UMP) Mucinous Neoplasm of Low Malignant Potential (M-LMP) Adenocarcinoma (Mucinous, Intestinal, and Signet Ring Types) Goblet Cell and Tubular Carcinoids Pseudomyxoma Peritonei Syndrome Conclusion References The Pathogenesis of Malignant Ascites Introduction Anatomical and Physiological Considerations Anatomy of the Peritoneal Membrane The Peritoneal Lymphatic System Characteristics of Malignant Ascites - Intraperitoneal Protein Accumulation Impaired Drainage or Increased Production?
3 Contents XI Starling s law of Capillary Hemodynamics Increased Capillary Permeability Increased Filtration Surface Area Increased Hydraulic Pressure Difference Decreased Oncotic Pressure Difference Conclusion References Natural History of Peritoneal Carcinomatosis from Digestive Origin Introduction Aetiology of Peritoneal Carcinomatosis Clinical Features of Peritoneal Carcinomatosis from Digestive Origin Gastric Cancer Colorectal Cancer Pancreatic Cancer Cancer with Unknown Primary Natural History of Peritoneal Carcinomatosis Discussion References Part 2. The Rationale for Intraperitoneal Heat and Drug Therapy 8. Intraperitoneal Drug Therapy: Physical and Biological Principles Background IP Versus Systemic (IV) Chemotherapy Pharmacokinetic Advantage Compartmental Approach to IP Pharmacokinetics Distributed Model and Challenges of the Peritoneal Barrier in Neoplasms Anatomic Peritoneum Interstitium and Tumour Microenvironment Microcirculation Summary of Neoplastic versus Normal Peritoneal Barrier Importance of Contact Area to Intraperitoneal Chemotherapy Penetration of Antineoplastic Agents Intraperitoneal Chemotherapy with Small Molecular Weight Drugs Intraperitoneal Therapy with Macromolecular Agents Acknowledgment References Current Status of Intraperitoneal Antineoplastic Drug Delivery Intraperitoneal Chemotherapy: Historical Perspective The Dedrick Model and Pre-clinical Evaluation of Intraperitoneal Chemotherapy Penetration of Cytotoxic Antineoplastic Agents into Tumour Tissue
4 XII Contents Drug Delivery by Direct Penetration versus Capillary Flow Phase I Trial Experience with Intraperitoneal Antineoplastic Drug Delivery156 Phase II Trials of Intraperitoneal Antineoplastic Drug Delivery Phase III Trials of Cisplatin-based Intraperitoneal Chemotherapy as Primary Treatment of Advanced Ovarian Cancer Options for Use of Primary IP Chemotherapy of Ovarian Cancer Other Potential Uses of Intraperitoneal Antineoplastic Drug Delivery in the Management of Ovarian Cancer Randomized Trial Experience with Intraperitoneal Antineoplastic Drug Delivery in Non-ovarian Cancers References The Biologic Rationale of Hyperthermia Abstract Introduction Basic Principles of Hyperthermic Cell Death Molecular and Cellular Effectors of Hyperthermia Alterations of the Tumour Microenvironment Hyperthermia and the Immune System Cellular Immune Response Heat Shock Proteins Summary References Interactions between Hyperthermia and Cytotoxic Drugs Abstract Introduction Principles of heat-drug interaction Hyperthermia and drug resistance Pharmacological studies Heat interactions of novel compounds Summary References Pharmacodynamic Aspects of Intraperitoneal Cytotoxic Therapy Introduction General Pharmacodynamic Aspects of Intraoperative Intraperitoneal Chemotherapy Pharmacodynamics of Cytotoxic Drugs used with HIPEC Alkylating Drugs Platinum Compounds Topoisomerase Interactive Agents Antimetabolites Antimicrotubule Agents Approaches to Increase Tumour Drug Distribution Increasing Drug Supply
5 Contents XIII Enhancing Drug Penetration Summary and Conclusion References Part 3. Cytoreductive Surgery for Peritoneal Carcinomatosis: Techniques and Methods 13. Patient Selection for Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion Introduction Indications for Cytoreduction and HIPEC Pseudomyxoma Peritonei Colorectal Cancer Gastric Cancer Ovarian Cancer Peritoneal Mesothelioma Peritoneal Sarcomatosis Patient Selection Preoperative Imaging Repeat Operations References Staging and Scoring of Peritoneal Carcinomatosis Introduction Extent of Prior Surgery Prior Surgery Score (PSS) Extent and Distribution of Disease Carcinomatosis Staging by the Japanese Research Society for Gastric Cancer (P-Score) Japanese Research Society for Gastric Cancer P-Score Gilly Staging for Peritoneal Carcinomatosis Peritoneal Cancer Index (PCI) Simplified Peritoneal Cancer Index Involved Regions (N-score) Assessment of Completeness or Extent of Surgery Completeness of Cytoreduction Score Residual Disease (R) - Score Extent of Surgery Extent of Surgery Score Level of Cytoreduction Conclusion References
6 XIV Contents 15. Peritonectomy Procedures Introduction Electroevaporative surgery Patient Positioning Construction of the Surgical Field to provide Simultaneous Exposure of the Abdomen and Pelvis Parietal Peritoneal Stripping from the Anterior Abdominal Wall Stripping the Visceral Peritoneum from the Surface of the Bladder Parietal Peritoneal Dissection to the Paracolic Sulcus and Beyond Peritoneal Stripping from Beneath the Left Hemidiaphragm Greater Omentectomy and Splenectomy with Completion of the Left Subphrenic Peritonectomy Peritoneal Stripping from Beneath the Right Hemidiaphragm Removal of an Envelope of Tumour from Beneath the Right Hemidiaphragm, from the Right Subhepatic Space, and from the Surface of the Liver Completed Right Subphrenic Peritonectomy Cholecystectomy with Resection of the Hepatoduodenal Ligament Circumferential Resection of the Hepatogastric Ligament and Lesser Omentum by Digital Dissection Limits of the Lesser Omentectomy with Stripping of the Floor of the Omental Bursa Limits of the Complete Pelvic Peritonectomy Resection of Rectosigmoid Colon, Uterus, and Cul-de-sac of Douglas Preparation for Perioperative Intraperitoneal Chemotherapy Discussion References Continuous Peritoneal Perfusion: Techniques, Methods and Applications Introduction Methods of Hyperthermic Intraperitoneal Chemotherapy Open Perfusion Methods Partially Closed and Closed Perfusion Methods Safety Considerations for HIPEC Technical Parameters of Hyperthermic Chemoperfusion Cytostatic Agents Suitable for HIPEC Intraperitoneal Temperature Carrier solution Volume Duration Flow rate Conclusions References Handling of Chemotherapeutic Drugs in the OR: Hazards and Safety Considerations Introduction
7 Contents XV Exposure and Effect Studies Routes and mechanisms of exposure Inhalation of Airborne Compounds Ingestion and Eye Contact Skin Contact Injection through Accidental Injury with Sharp Tools Recommendations for Safety Precautions Organizational measures Use of Technical and Personal Protective Equipment Spill Management, Cleaning and Decontamination Protocols Proper Waste Handling and Disposal Information and Training Medical Surveillance and Monitoring References Part 4. Clinical Results of Surgery with or without Intraperitoneal Heated Drug Therapy 18. Results of Cytoreduction followed by HIPEC in Carcinomatosis of Colorectal Origin Introduction Surgery for Peritoneal Carcinomatosis of Colorectal Origin Prognostic Factors Completeness of Cytoreduction Extent of Disease before Surgery Other Prognostic Factors Complications of Surgery The Learning Curve of Cytoreduction with HIPEC Conclusion References HIPEC with Oxaliplatin in the Treatment of Peritoneal Carcinomatosis of Colorectal Origin Introduction Patient Eligibility and Surgical Procedures Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Results of a Phase I Study of HIPEC with Oxaliplatin Methods Results Conclusion Results of a Phase I Study with Oxaliplatin using Hypotonic Solutions Introduction Methods Results
8 XVI Contents Results of a Phase II Study of HIPEC with Oxaliplatin Patients and methods Results Discussion Conclusion Comparison of HIPEC with Oxaliplatin versus Standard Systemic Chemotherapy HIPEC group Standard Group Overall survival rates Discussion Phase I study of HIPEC combining Oxaliplatin and Irinotecan Methods Results Conclusion Relation between the Extent of Cytoreductive surgery and the Rate of Postoperative Hematological Toxicity Background Methods Results Conclusion Future Directions and Conclusion Aknowledgement References Clinical Results of Cytoreduction and HIPEC in Pseudomyxoma Peritonei Introduction Site of Origin of PMP Pathological Classification of Appendiceal Neoplasms Clinical Trials of Cytoreduction and Intraperitoneal Chemotherapy Conclusion References The Impact of Therapy in the Treatment of Pseudomyxoma Peritonei. 329 Introduction Memorial Sloan-Kettering Cancer Center Experience Methods Clinicopathologic Features Operative Results Long term overall survival Evaluating the Impact of Therapy for PMP References
9 Contents XVII 22. Clinical Results of Cytoreduction and HIPEC for Malignant Peritoneal Mesothelioma Introduction Results of Cytoreduction and HIPEC Summary References Cytoreduction and Intraperitoneal Chemotherapy for Carcinomatosis from Gastric Cancer Introduction Diagnosis of Peritoneal Carcinomatosis Results of Systemic Chemotherapy in the Treatment of PC of Gastric Origin Treatment of PC of Gastric Origin with Intraperitoneal Chemotherapy Perioperative Intraperitoneal Chemotherapy Neoadjuvant Intraperitoneal and Systemic Chemotherapy Hyperthermic Intraperitoneal Chemoperfusion Early Postoperative Intraperitoneal Chemotherapy Peritonectomy Procedures Conclusion References Cytoreduction and Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Cancer Introduction Cytoreductive Surgery Hyperthermic Intraperitoneal Chemotherapy Intraperitoneal Chemotherapy Intraperitoneal Hyperthermic Chemotherapy Effects of HIPEC Refractory Ovarian Cancer Prognostic Factors Affecting Patient Survival Conclusion References The role of Neoadjuvant Chemotherapy versus Primary Surgery in the Management of Stage III Ovarian Cancer Introduction Primary Cytoreductive Surgery Biological basis of Cytoreductive Surgery Optimal versus Suboptimal Cytoreductive Surgery Variables influencing Cytoreductive Surgery Outcome of Cytoreductive Surgery FIGO Stage IV Disease Neoadjuvant Chemotherapy and Interval Cytoreduction Neoadjuvant Chemotherapy followed by Interval Cytoreduction after Suboptimal Primary Cytoreduction
10 XVIII Contents Neoadjuvant Chemotherapy followed by Interval Cytoreduction as an Alternative to Primary Cytoreduction Laparoscopy to select Patients for Neoadjuvant Chemotherapy References Morbidity and Quality of Life following Cytoreduction and HIPEC Introduction Morbidity and Mortality following Cytoreduction and HIPEC Milano National Cancer Institute Experience Bowel Complications following Cytoreduction and HIPEC Quality of Life following Cytoreduction and HIPEC References Detection and Treatment of Recurrent Disease after Cytoreduction and HIPEC Follow-up after Cytoreduction Treatment of Recurrent Disease References Part 5. Nonoperative and Multimodal Management of Peritoneal Carcinomatosis 28. Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis from Colorectal Cancer Introduction Peritoneal Carcinomatosis in Trials of Systemic Chemotherapy Systemic Therapy with 5-Fluorouracil New cytotoxic drugs: Irinotecan and Oxaliplatin Oral Fluoropyrimidines Antibodies in Treatment of Colorectal Cancer Treatment strategy References Systemic Chemotherapy in patients with Peritoneal Carcinomatosis from Non Colorectal Origin Introduction Systemic Therapy Conclusion References The Role of Radiotherapy in the treatment of Peritoneal Carcinomatosis Introduction PC Originating from Gastrointestinal Cancers PC Originating from Gynaecological Cancers
11 Contents XIX PC Originating from Other Cancers Conclusions and Future Prospects for Radiotherapy - the Role of Intensity Modulated Arc Therapy References Medical and Palliative Management of Malignant Ascites Introduction Pathophysiology and Diagnosis Symptomatic Management by Paracentesis Symptomatic Management by Diuretics Symptomatic Management by Peritoneovenous Shunts New Treatments Management of Symptomatic Malignant Ascites References Part 6. Experimental Approaches 32. Targeted Intraabdominal Chemotherapy for Peritoneal Carcinomatosis Summary Intentions and Basic Concepts of Targeted Chemotherapy Clinical Experience Experimental Evidence Animals and Experimental Design Cell Culture and Tumour Cell Inoculation Intraperitoneal Treatment Assessment of Peritoneal Tumour spread, Tumour Growth and Response to Treatment Tumour Growth and Response to Treatment Discussion Perspectives References Immunotherapy of Peritoneal Carcinomatosis Immunological Defence Mechanisms of the Peritoneal Cavity Unspecific Immunotherapy/Cytokines Stimulation of Immunocompetent Cells by Defined Cytokines Antibody Constructs Summary References Intraperitoneal Photodynamic Therapy Introduction Mechanisms of PDT Mediated Cell Death Preclinical Studies of Intraperitoneal PDT
12 XX Contents Clinical Applications of Intraperitoneal PDT New Frontiers in Intraperitoneal PDT: Molecularly Targeted Therapy Summary and Conclusions References Intraperitoneal Gene Therapy Introduction Vectors Gene Therapy Strategies Targeting p53 tumour suppressor gene Targeting HER-2/neu proto-oncogene Other adenovirus based approaches Experimental Approaches Conclusion References Index
13
Patient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationInformation for health professionals - pseudomyxoma peritonei
Colorectal and peritoneal oncology centre Information for health professionals - pseudomyxoma peritonei What is it? Pseudomyxoma Peritonei (PMP) is often a slowly progressive disease that produces extensive
More informationPre-operative assessment of patients for cytoreduction and HIPEC
Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive
More informationDepartment of Surgery, Kusatsu General Hospital, Yabase Kusatsu 1660, Japan 2
Gastroenterology Research and Practice Volume 2012, Article ID 836425, 5 pages doi:10.1155/2012/836425 Clinical Study Morbidity and Mortality Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal
More informationPeritonectomy plus hyperthermic peritoneal perfusion for the treatment of peritoneal carcinosis H. Müller, MD, FACS
Peritonectomy plus hyperthermic peritoneal perfusion for the treatment of peritoneal carcinosis H. Müller, MD, FACS Department of surgical oncology, Carl von Hess hospital, Hammelburg, Germany www.klinik-hammelburg.de
More informationJoseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital
Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital jmisdraji@partners.org Low-grade appendiceal mucinous neoplasm (LAMN) High-grade appendiceal mucinous neoplasm (HAMN) Adenocarcinoma
More informationCorporate Medical Policy
Corporate Medical Policy Hyperthermic Intraperitoneal Chemotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hyperthermic_intraperitoneal_chemotherapy 5/19/2005 3/2018 3/2019
More informationManagement of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Surgical Oncology Department Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). 21/04/2010 THERMOMETRY 1000-1500
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cytoreduction and Hyperthermic Page 1 of 10 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the
More informationCytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease. Results of the French multicentric database
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease Results of the French multicentric database Université Lyon 1 Centre Hospitalo-Universitaire Lyon-Sud EA
More informationPseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES
Pseudomyxoma peritoni et al HOW TO TREAT PERITONEAL MALIGNANCIES Case Presentation 72M 3 weeks abdominal distension and lower abdominal pain. 3 weeks constipation w/ 2-3 BM per week. Post-prandial epigastric/substernal
More informationHIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies
HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies Crescent City Cancer Update: GI and HPB Saturday September 24, 2016 George M. Fuhrman,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cytoreductive Surgery and Perioperative Intraperitoneal Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cytoreductive Surgery and Perioperative Intraperitoneal
More informationCytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei
Int J Colorectal Dis (2005) 20:155 160 DOI 10.1007/s00384-004-0648-7 O R I G I N A L A R T I C L E Z. Güner U. Schmidt M. H. Dahlke H. J. Schlitt J. Klempnauer P. Piso Cytoreductive surgery and intraperitoneal
More informationCRS e HIPEC: Efficacia e Limiti
CRS e HIPEC: Efficacia e Limiti Marcello Deraco M.D. Responsabile Tumori Peritoneali The Concept of Cytoreductive Surgery Means a complete removal of all macroscopic tumor in the peritoneal cavity; It
More informationMP Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Medical Policy MP 2.03.07 Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic BCBSA Ref. Policy: 2.03.07 Last Review: 07/25/2018 Effective Date: 07/25/2018
More informationINTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION
INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationSpecialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei
Specialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) of Pseudomyxoma Peritonei Document Author: Assistant Medical Director Executive Lead: Medical Director Approved by: Management
More informationTREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS
TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS Anna Lepistö, MD, PhD Department of Colorectal Surgery, Abdominal Center, Helsinki University Hospital Incidence, prevalence and risk factors for peritoneal
More informationHeated Intraperitoneal Chemotherapy (HIPEC) for Advanced Abdominal Cancers
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/heated-intraperitonealchemotherapy-hipec-for-advanced-abdominal-cancers/7091/
More informationRationale for the treatment. Peritoneal Surface Malignancy
Rationale for the treatment of Peritoneal Surface Malignancy K. Van der Speeten 05/10/12 A full circle :acknowledgements Rationale for the treatment of Peritoneal Surface Malignancy K. Van der Speeten
More informationMP Hyperthermic Intraperitoneal Chemotherapy for Select IntraAbdominal and Pelvic Malignancies. Related Policies None
Medical Policy MP 2.03.07 BCBSA Ref. Policy: 2.03.07 Last Review: 10/18/2018 Effective Date: 01/25/2019 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationCytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Last Review Status/Date: December 2016 Page: 1 of 29 Intraperitoneal Chemotherapy for Select Intra- Description Cytoreductive surgery (CRS) comprises peritonectomy (ie, peritoneal stripping) procedures
More informationClinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma Peritonei of Appendiceal Origin
Gastroenterology Research and Practice Volume 2012, Article ID 981245, 5 pages doi:10.1155/2012/981245 Clinical Study Laparoscopic Cytoreductive Surgery and HIPEC in Patients with Limited Pseudomyxoma
More informationResults of CRS and HIPEC in. Colorectal PSM. and. Pseudomyxoma Peritonei
Results of CRS and HIPEC in Colorectal PSM and Pseudomyxoma Peritonei K. Van der Speeten 05/10/12 Introduction Results Morbidity & Mortality Adjuvant HIPEC Conclusions K. Van der Speeten Introduction PSM
More informationClinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers Reference Number: CP.MP. 346
Clinical Policy: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Reference Number: CP.MP. 346 Effective Date: 11/15 Last Review Date: 11/17 See Important Reminder at the end of this policy
More informationReview of a Personal Experience in the Management of Carcinomatosis and Sarcomatosis
Jpn J Clin Oncol 2001;31(12)573 583 Special Article Review of a Personal Experience in the Management of Carcinomatosis and Sarcomatosis Paul H. Sugarbaker Washington Cancer Institute, Washington, DC,
More informationCytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Last Review Status/Date: March 2015 Page: 1 of 32 Intraperitoneal Chemotherapy for Select Intra- Description Pseudomyxoma peritonei describes extensive mucus accumulation within the peritoneum resulting
More informationCRS and HIPEC for Peritoneal Carcinomatosis : An update and critical appraisal
CRS and HIPEC for Peritoneal Carcinomatosis : An update and critical appraisal K. Van der Speeten, MD, PhD Pretoria 08/10/16 2016 : the Good, the Bad and the Ugly Chemosurgery The surgery in chemosurgery
More informationRegional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
More informationAandachtspunten bij Anesthesie voor HIPEC. Marleen Verhaegen
Aandachtspunten bij Anesthesie voor HIPEC Marleen Verhaegen 22-11-2013 Outline Rationale en techniek van HIPEC Temperatuurbeleid Vochtbeleid Peritoneale perfusie in glucose 5 % (oxaliplatin) Specifieke
More informationRegional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
More informationSurgical Department, Didimotichon General Hospital, Didimotichon, Greece 2
Hindawi Publishing Corporation Journal of Oncology Volume 22, Article ID 35834, 6 pages doi:.55/22/35834 Clinical Study Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy
More informationAbstract. Materials and methods
Int J Gynecol Cancer 2006, 16, 490 495 Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures A.-A.K. TENTES, C.G. MIRELIS, S.K. MARKAKIDIS,
More informationA Case of Mucinous Cystadenocarcinoma Ovary Mimicking Psuedomyxoma Peritonei
A Case of Mucinous Cystadenocarcinoma Ovary Mimicking Psuedomyxoma Peritonei Dr. Abdul haleem & Dr. Vishwanath sherigar Department of General Surgery, K S Hegde Medical Academy, Mangalore, Karnataka, India
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More information1. Introduction. Correspondence should be addressed to Horacio N. López-Basave, Received 23 May 2011; Accepted 20 June 2011
International Scholarly Research Network ISRN Oncology Volume 2011, Article ID 526384, 6 pages doi:10.5402/2011/526384 Research Article Morbidity and Mortality of Cytoreductive Surgery with Hyperthermic
More informationHyperthermic Intraperitoneal Chemotherapy
Hyperthermic Intraperitoneal Chemotherapy Acta chir belg, 2006, 106, 276-282 Surgery for Peritoneal Carcinomatosis from Colorectal Origin : Techniques and Limitations W. P. Ceelen Surgical Oncology, University
More informationBeate Rau, Charité University of Berlin Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR
Chairs Beate Rau, Charité University of Berlin Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR Faculty members Frédéric Bibeau, Caen University
More informationBeate Rau, Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR
Chairs Beate Rau, Campus Virchow-Klinikum, Berlin, DE François Quenet, Centre Régional du Cancer, Montpellier, Montpellier, FR Faculty members Salah-Eddin Al-Batran, Institut für Klinisch-Onchologische
More informationis time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the
My name is Barry Feig. I am a Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. I am going to talk to you today about the role for surgery in the treatment
More informationNever mistake knowledge for wisdom. One helps you make a living; the other helps you make a life.
Never mistake knowledge for wisdom. One helps you make a living; the other helps you make a life. -Sandra Carey In honour of God and to my loving wife, Helena, and our children List of Papers This thesis
More informationHyperthermic Intraperitoneal Chemotherapy (HIPEC)
Medical Coverage Policy Effective Date...10/15/2017 Next Review Date...10/15/2018 Coverage Policy Number... 0396 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Table of Contents Related Coverage Resources
More informationManagement of an Appendiceal Mass - Approach to acute presentation of appendiceal neoplasms
Management of an Appendiceal Mass - Approach to acute presentation of appendiceal neoplasms Dr. Claudia LY WONG, Department of Surgery, Kwong Wah Hospital Joint Hospital Surgical Grand Round Presentation,
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedures overview of complete cytoreduction Introduction (Sugarbaker technique) for pseudomyxoma peritonei
More informationKathleen A. Cummins 1, Gregory B. Russell 2, Konstantinos I. Votanopoulos 1, Perry Shen 1, John H. Stewart 1, Edward A. Levine 1.
Original Article Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) Kathleen A. Cummins 1, Gregory
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal surgery prior as factor in laparoscopic colorectal surgery, 554 555 Abscess(es) CRC presenting as, 539 540 Adenocarcinoma of
More informationClinical presentation of the pseudomyxoma peritonei syndrome
Original article Clinical presentation of the pseudomyxoma peritonei syndrome J. Esquivel and P. H. Sugarbaker Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA Correspondence
More informationPlanned relaparotomy following curative resection of a locally advanced gastrointestinal cancer
Planned relaparotomy following curative resection of a locally advanced gastrointestinal cancer PD Dr. med. Michel Adamina, MSc Department of Surgery Agenda Prerequisite for successful CRS HIPEC Planned
More informationDespite advances in our understanding of appendiceal. An Update on the Diagnosis, Grading, and Staging of Appendiceal Mucinous Neoplasms
REVIEW ARTICLE An Update on the Diagnosis, Grading, and Staging of Appendiceal Mucinous Neoplasms Mark A. Valasek, MD, PhD* and Reetesh K. Pai, MD Abstract: Despite advances in our understanding of appendiceal
More informationHeated intraperitoneal chemotherapy and gastrectomy for gastric cancer in the U.S.: the time is now
Short Communication Heated intraperitoneal chemotherapy and gastrectomy for gastric cancer in the U.S.: the time is now Zachary J. Brown, Jonathan M. Hernandez, R. Taylor Ripley, Jeremy L. Davis Thoracic
More informationHyperthermic intraperitoneal chemotherapic perfusion in colorectal cancer
Review Article Hyperthermic intraperitoneal chemotherapic perfusion in colorectal cancer Pedro Bretcha-Boix, Jose Farre-Alegre USP Hospital San Jaime, Torrevieja, Spain Corresponding to: Pedro Bretcha-Boix,
More informationSurgical Oncology, Mercy Medical Center, Baltimore, MD
Ann Surg Oncol (2012) 19:110 114 DOI 10.1245/s10434-011-1840-y ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY The Role of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy (CRS/HIPEC) in Patients
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationINTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)
UnitedHealthcare Commercial Medical Policy INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) Policy Number: SUR052 Effective Date: January 1, 2019 Table of Contents Page INSTRUCTIONS FOR
More informationClinical Study Adjuvant Perioperative Intraperitoneal Chemotherapy in Locally Advanced Colorectal Carcinoma: Preliminary Results
International Scholarly Research Network ISRN Surgery Volume 2011, Article ID 529876, 6 pages doi:10.5402/2011/529876 Clinical Study Adjuvant Perioperative Intraperitoneal Chemotherapy in Locally Advanced
More informationColorectal peritoneal metastases and IMPACT
Colorectal peritoneal metastases and IMPACT Vicki Pleavin-Evans Peritoneal Malignancy Clinical Nurse Specialist PMI Basingstoke Basingstoke and North Hampshire Hospital Aldermaston Road, Basingstoke, Hampshire
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Case Report Pseudomyxoma Peritonei: A Rare Presentation Dr. B. Ananda Rama Rao 1, Dr. P. Saikumar 2, Dr. J. Srikanth
More informationHepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Ann Surg Oncol (2011) 18:1052 1059 DOI 10.1245/s10434-010-1415-3 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Hepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal
More informationCRS and HIPEC for Colorectal Cancer. Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017
CRS and HIPEC for Colorectal Cancer Rajesh Nair, MD UF Health Cancer Center-Orlando Health March 11, 2017 Peritoneal Carcinomatosis from CRC Historically, a devastating problem Extreme morbidity from disease
More informationORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY. Ann Surg Oncol (2011) 18: DOI /s
Ann Surg Oncol (2011) 18:1575 1581 DOI 10.1245/s10434-011-1631-5 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients
More informationKey words: appendiceal carcinoma; peritonectomy; intraperitoneal chemotherapy.
EJSO 2001; 27: 286 290 doi:10.1053/ejso.2000.1095, available online at http://www.idealibrary.com on Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy
More informationCytoreduction including total gastrectomy for pseudomyxoma peritonei
Original article Cytoreduction including total gastrectomy for pseudomyxoma peritonei P. H. Sugarbaker Washington Cancer Institute, 110 Irving Street NW, Washington, DC 20010, USA Correspondence to: Dr
More informationQué operar y que no operar en carcinomatosis peritoneal. Indicaciones y límites.
Qué operar y que no operar en carcinomatosis peritoneal. Indicaciones y límites. Dr. Pere Bretcha Boix Plataforma de Oncología Hospital quironsalud Torrevieja 1 20-year survival of 70% 2 Appendiceal Neoplasms
More informationVic J. Verwaal, MD, PhD, 1 Sjoerd Bruin, MD, 1 Henk Boot, MD, PhD, 2 Gooike van Slooten, MD, 1 and Harm van Tinteren, ScM 3
Annals of Surgical Oncology 15(9):2426 2432 DOI: 10.1245/s10434-008-9966-2 8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy
More informationShort bowel syndrome after cytoreductive surgery and HIPEC: nutritional considerations
JBUON 2014; 19(2): 549-553 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Short bowel syndrome after cytoreductive surgery and HIPEC: nutritional
More informationProf. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationThis is a submitted version of a paper published in European Journal of Surgical Oncology. Access to the published version may require subscription.
Uppsala University This is a submitted version of a paper published in European Journal of Surgical Oncology. Citation for the published paper: Cashin, P., Graf, W., Nygren, P., Mahteme, H. (2012) "Cytoreductive
More informationFINAL SCIENTIFIC PROGRAMME
FINAL SCIENTIFIC PROGRAMME AGENDA Day 1 Speaker Chairpersons 8:30 AM 8:45 AM 8:45 AM 9:00 AM Intraperitoneal chemotherapytypes, techniques, tips Choice of drugs and carrier solutions for intraperitoneal
More informationSurgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer
Ovarian cancer Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer JM. Classe, R. Rouzier, O.Glehen, P.Meeus, L.Gladieff, JM. Bereder, F Lécuru Suitable candidates for neo-adjuvant
More informationONLINE CONTINUING EDUCATION ACTIVITY
ONLINE CONTINUING EDUCATION ACTIVITY Take free quizzes online at acsjournals.com/ce ARTICLE TITLE: Looking Up: Recent Advances in Understanding and Treating Peritoneal Carcinomatosis CONTINUING MEDICAL
More informationCURRICULUM VITAE 2005
CURRICULUM VITAE 2005 Last Name : GLEHEN Fist Name: Olivier Current Address Department of Surgical Oncology University Hospital of LYON-SUD 69695 Pierre Bénite, France e-mail : olivier.glehen@chu-lyon.fr
More informationDisseminated Peritoneal Adenomucinosis Associated with a Panperitonitis-Like Onset: Report of a Case
Surg Today (2001) 31:646 650 Disseminated Peritoneal Adenomucinosis Associated with a Panperitonitis-Like Onset: Report of a Case Yoshito Kuroki 1, Shunyou Otagiri 1, and Kazuhiro Tsukada 2 1 Department
More informationA new scoring system for peritoneal metastasis in gastric cancer
Gastric Cancer (2003) 6: 146 152 DOI 10.1007/s10120-003-0243-6 2003 by International and Japanese Gastric Cancer Associations Original article A new scoring system for peritoneal metastasis in gastric
More informationUsing Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
72 Current Drug Discovery Technologies, 2009, 6, 72-81 Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy Kurt Van der Speeten 1, Oswald Anthony Stuart
More informationClinicopathological features and prognosis of pseudomyxoma peritonei
EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 185-190, 2014 Clinicopathological features and prognosis of pseudomyxoma peritonei HUAN WANG 1*, XUEJUN WANG 2*, YANFANG JU 1, JINLIANG WANG 1, XIN ZHANG 1, YAO
More informationBasic Data. Birthday: Gender:Female Admission date:
Basic Data Birthday:1951-07-02 Gender:Female Admission date:2004-06-28 Chief Complaint A protruding mass over RLQ abdomen for many years. Present Illness & Past History Pseudomyxoma peritonei s/p laparotomy
More informationAppendix adenocarcinomas are rare and heterogeneous
ORIGINAL CONTRIBUTION Predicting Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendix Adenocarcinoma Omer Aziz, Ph.D., F.R.C.S. 1,2 Ihab Jaradat, F.R.C.S. 1 Bipasha
More informationPurpose. Page 2 of 24
Accuracy of MDCT in the preoperative definition of peritoneal cancer index (PCI) in patients with advanced ovarian cancer who underwent peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC)
More informationPhase II Trial of Debulking Surgery and Photodynamic Therapy for Disseminated Intraperitoneal Tumors
Annals of Surgical Oncology, 8(1):65 71 Published by Lippincott Williams & Wilkins 2001 The Society of Surgical Oncology, Inc. Phase II Trial of Debulking Surgery and Photodynamic Therapy for Disseminated
More informationBeate Rau, Charité Campus Berlin, Berlin, DE Tom Cecil, Basingstoke and North Hampshire Hospital, Basingstoke, UK
Chairs Beate Rau, Charité Campus Berlin, Berlin, DE Tom Cecil, Basingstoke and North Hampshire Hospital, Basingstoke, UK Faculty members Andreas Brandl, Charité Campus Berlin, Berlin, DE James Coakes,
More informationHyperthermic intraperitoneal chemotherapy in peritoneal surface malignancy Witkamp, A.J.
UvA-DARE (Digital Academic Repository) Hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancy Witkamp, A.J. Link to publication Citation for published version (APA): Witkamp, A. J.
More informationDebulking Surgery and HIPC to Treat Ovarian Cancer
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/debulking-surgery-and-hipc-to-treat-ovariancancer/3690/
More informationSummary and Future Perspectives
Summary and Future Perspectives Summary and Future Perspectives General Summary Metastatic disease (Stage IV) is present in approximately 20% of patients with colorectal cancer (CRC) at time of diagnosis.
More informationPeritoneal dissemination is a common manifestation of disease
ORIGINAL ARTICLE Identification of a Subgroup of Patients at Highest Risk for Complications After Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Dario Baratti, MD, Shigeki Kusamura,
More informationExploring Anatomy: the Human Abdomen
Exploring Anatomy: the Human Abdomen PERITONEUM AND PERITONEAL CAVITY PERITONEUM The peritoneum is a thin serous membrane that lines the abdominal cavity and covers, in variable amounts, the viscera within
More informationHIPEC treatment of peritoneal carcinomatosis in colorectal and gastric cancer Braam, Hidde
UvA-DARE (Digital Academic Repository) HIPEC treatment of peritoneal carcinomatosis in colorectal and gastric cancer Braam, Hidde Link to publication Citation for published version (APA): Braam, H. J.
More informationSummary of the study protocol of the FLOT3-Study
Summary of the study protocol of the FLOT3-Study EudraCT no. 2007-005143-17 Protocol Code: S396 Title A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients
More informationBY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
More informationWorld Journal of Colorectal Surgery
World Journal of Colorectal Surgery Volume 6, Issue 4 2016 Article 3 Laparoscopic Right Colectomy For Appendiceal Mucinous Cystadenoma: A Case Report Dion A. Putra Adianto Nugroho Ibrahim Basir University
More informationReview Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer
Review Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer Andrea Jewell 1, Megan McMahon 1 and Dineo Khabele 1 1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology,
More informationManagement of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Cytoreductive Surgery (CRS)
Management of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Cytoreductive Surgery (CRS) 19-21 MARCH 2015 HAMBURG EUROPEAN SCHOOL OF PERITONEAL SURFACE ONCOLOGY Management of Hyperthermic Intraperitoneal
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationCase Report Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Unconventional Indications
Cronicon OPEN ACCESS CANCER Case Report Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Unconventional Indications Chin Jin Seo 1, Grace Hwei Ching Tan 2 *, Kee Chee Soo 1,2 and Melissa
More informationtumor. CRS? HIPEC was well tolerated in our selected patients with PC, some of whom had improved survival.
Ann Surg Oncol (29) 16:345 351 DOI 1.45/s1434-8-226-2 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival in Selected Patients
More informationCOLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini
UNIVERSITY OF PERUGIA Department of General and Emergency Surgery Chief: Prof. Annibale Donini COLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini COLON CANCER IS A HIGHLY FREQUENT NEOPLASIA
More informationCase Scenario 1. 1/2/13 History: 64-year-old white female presented with right leg swelling and redness, abdominal pain.
Case Scenario 1 1/2/13 History: 64-year-old white female presented with right leg swelling and redness, abdominal pain. 1/02/13 CT Abdomen/Pelvis: Abnormal area of nodular mesenteric and left anterior
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors Irene Thomassen 1,2, Yvette R. van Gestel 2, Bert van Ramshorst
More informationReview Article Pulmonary Metastasis from Pseudomyxoma Peritonei
Gastroenterology Research and Practice Volume 2012, Article ID 690256, 6 pages doi:10.1155/2012/690256 Review Article Pulmonary Metastasis from Pseudomyxoma Peritonei Toshiyuki Kitai Department of Surgery,
More informationIntraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence
reviews Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence Wim P. Ceelen and Michael F. Flessner Abstract In patients with tumors confined to the peritoneal cavity, there is
More information